CRDF

Cardiff Oncology, Inc.

Price Chart

Latest Quote

$1.21

+0.03 (+2.54%)

Current Price

Previous Close	$1.18
Open	$1.20
Day High	$1.29
Day Low	$1.20
Volume	928,845

Fetched: 2026-06-20T06:00:45

Stock Information

Shares Outstanding	68.37M
Total Debt	$646K
Cash Equivalents	$46.06M
Revenue	$525K
Net Income	$-44.79M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$82.73M
EPS (TTM)	$-0.67
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$37.32M
Sales	$525K
Income	$-44.79M
Book/sh	$0.51
Cash/sh	$0.67
Employees	30

Financial Ratios

Quick Ratio	3.20
Current Ratio	3.27
Debt/Eq	1.86

Returns & Margins

ROA	-44.25%
ROE	-84.79%
Operating Margin	-31341.46%

Ownership

Insider Ownership	5.91%
Institutional Ownership	32.85%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.49
P/S	157.58
P/B	2.38

Analyst Data

Recommendation	buy
Target Price	$5.36

Technical Indicators

SMA20	$1.56
SMA50	$1.63
SMA200	$2.02
RSI	25.18
ATR	0.1757

Shares Float	66.60M
Short Float	27.15%
Short Ratio	18.17
Volatility	1.38
Rel Volume	0.56

Performance History

Week	-23.90%
Month	-31.25%
Quarter	-33.52%
6 Months	-49.58%
YTD	-54.51%
Year	-67.30%
3 Years	-24.37%
5 Years	-84.64%
10 Years	-99.64%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$1.21	960,600
2026-06-17	$1.18	1,614,100
2026-06-16	$1.26	1,725,800
2026-06-15	$1.42	1,286,200
2026-06-12	$1.54	806,200
2026-06-11	$1.59	1,306,400
2026-06-10	$1.48	1,197,700
2026-06-09	$1.53	1,363,500
2026-06-08	$1.50	854,900
2026-06-05	$1.50	2,816,800
2026-06-04	$1.55	1,722,300
2026-06-03	$1.40	2,503,400
2026-06-02	$1.51	2,711,900
2026-06-01	$1.48	5,919,500
2026-05-29	$1.90	783,800
2026-05-28	$1.84	857,900
2026-05-27	$1.81	1,056,500
2026-05-26	$1.94	1,832,200
2026-05-22	$1.78	1,262,100
2026-05-21	$1.79	1,539,500
2026-05-20	$1.84	1,768,200
2026-05-19	$1.76	3,143,200

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

📰 Latest News

Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist

Simply Wall St. • 2026-05-20T18:05:12Z

Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar

MarketBeat • 2026-03-25T22:11:02Z

Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC

MarketBeat • 2026-02-26T09:32:38Z

Cardiff Oncology: Q4 Earnings Snapshot

Associated Press Finance • 2026-02-24T22:26:41Z

Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team

Simply Wall St. • 2026-01-29T11:12:13Z

Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study

MarketBeat • 2026-01-27T15:54:31Z

3 Promising Penny Stocks With Market Caps Below $600M

Simply Wall St. • 2026-01-22T18:05:42Z

3 Penny Stocks With At Least $100M Market Cap

Simply Wall St. • 2025-12-22T18:05:23Z

Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most

Simply Wall St. • 2025-12-10T13:50:30Z

Cardiff Oncology: Q3 Earnings Snapshot

Associated Press Finance • 2025-11-06T21:33:44Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$593,000	$683,000	$488,000	$386,000
Operating Revenue	$593,000	$683,000	$488,000	$386,000
Expenses
Total Expenses	$49,553,000	$49,334,000	$45,900,000	$40,288,000
Other Income Expense	$5,000	$-39,000	$-98,000	$-383,000
Other Non Operating Income Expenses	$5,000	$-39,000	$-98,000	$-383,000
Net Non Operating Interest Income Expense	$3,104,000	$3,259,000	$4,069,000	$1,581,000
Operating Expense	$49,553,000	$49,334,000	$45,900,000	$40,288,000
General And Administrative Expense	$14,224,000	$12,482,000	$13,043,000	$13,181,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Net Interest Income	$3,104,000	$3,259,000	$4,069,000	$1,581,000
Interest Income	$3,104,000	$3,259,000	$4,069,000	$1,581,000
Normalized Income	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Net Income From Continuing And Discontinued Operation	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Total Operating Income As Reported	$-48,960,000	$-48,651,000	$-45,412,000	$-39,902,000
Net Income Common Stockholders	$-45,876,000	$-45,455,000	$-41,465,000	$-38,728,000
Net Income	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Net Income Including Noncontrolling Interests	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Net Income Continuous Operations	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Pretax Income	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Interest Income Non Operating	$3,104,000	$3,259,000	$4,069,000	$1,581,000
Operating Income	$-48,960,000	$-48,651,000	$-45,412,000	$-39,902,000
Per Share
Diluted EPS	$-0.69	$-0.95	$-0.93	$-0.89
Basic EPS	$-0.69	$-0.95	$-0.93	$-0.89
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-48,056,000	$-47,708,000	$-45,014,000	$-39,666,000
Reconciled Depreciation	$904,000	$943,000	$398,000	$236,000
EBITDA (Bullshit earnings)	$-48,056,000	$-47,708,000	$-45,014,000	$-39,666,000
EBIT	$-48,960,000	$-48,651,000	$-45,412,000	$-39,902,000
Diluted Average Shares	$66,841,000	$47,650,000	$44,677,000	$43,600,000
Basic Average Shares	$66,841,000	$47,650,000	$44,677,000	$43,600,000
Diluted NI Availto Com Stockholders	$-45,876,000	$-45,455,000	$-41,465,000	$-38,728,000
Preferred Stock Dividends	$25,000	$24,000	$24,000	$24,000
Research And Development	$35,329,000	$36,852,000	$32,857,000	$27,107,000
Selling General And Administration	$14,224,000	$12,482,000	$13,043,000	$13,181,000
Other Gand A	$6,934,000	$6,096,000	$6,282,000	$6,826,000
Salaries And Wages	$7,290,000	$6,386,000	$6,761,000	$6,355,000
Total Unusual Items	-	-	-	-
Total Unusual Items Excluding Goodwill	-	-	-	-
Gain On Sale Of Security	-	-	-	-

Fetched: 2026-06-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$45,388,000	$82,949,000	$69,739,000	$106,343,000
Total Assets	$61,884,000	$97,190,000	$81,637,000	$116,191,000
Total Non Current Assets	$1,756,000	$2,136,000	$4,225,000	$4,907,000
Other Non Current Assets	$549,000	$69,000	$1,279,000	$1,387,000
Current Assets	$60,128,000	$95,054,000	$77,412,000	$111,284,000
Other Current Assets	$1,642,000	$2,535,000	$2,301,000	$5,246,000
Receivables	$182,000	$773,000	$288,000	$771,000
Accounts Receivable	$182,000	$773,000	$288,000	$771,000
Cash Cash Equivalents And Short Term Investments	$58,304,000	$91,746,000	$74,823,000	$105,267,000
Cash And Cash Equivalents	$17,470,000	$51,470,000	$21,655,000	$16,347,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$832,000	$1,523,000	$2,149,000	$2,715,000
Long Term Debt And Capital Lease Obligation	$102,000	$813,000	$1,458,000	$2,040,000
Current Debt And Capital Lease Obligation	$730,000	$710,000	$691,000	$675,000
Liabilities
Total Liabilities Net Minority Interest	$16,496,000	$14,241,000	$11,898,000	$9,848,000
Total Non Current Liabilities Net Minority Interest	$102,000	$813,000	$1,458,000	$2,040,000
Current Liabilities	$16,394,000	$13,428,000	$10,440,000	$7,808,000
Payables And Accrued Expenses	$13,234,000	$9,972,000	$7,012,000	$5,284,000
Payables	$8,831,000	$4,821,000	$1,966,000	$1,956,000
Other Payable	$744,000	-	-	-
Accounts Payable	$8,087,000	$4,821,000	$1,966,000	$1,956,000
Dividends Payable	-	-	-	$0
Derivative Product Liabilities	-	-	-	-
Other Current Liabilities	-	-	-	-
Equity
Common Stock Equity	$45,388,000	$82,949,000	$69,739,000	$106,343,000
Total Equity Gross Minority Interest	$45,388,000	$82,949,000	$69,739,000	$106,343,000
Stockholders Equity	$45,388,000	$82,949,000	$69,739,000	$106,343,000
Gains Losses Not Affecting Retained Earnings	$50,000	$34,000	$-67,000	$-395,000
Other Equity Adjustments	$50,000	$34,000	$-67,000	$-395,000
Retained Earnings	$-430,030,000	$-384,179,000	$-339,541,000	$-298,100,000
Preferred Stock Equity	-	-	-	-
Other Equity Interest	-	-	-	-
Other
Ordinary Shares Number	$68,305,000	$66,524,182	$44,677,000	$44,677,000
Share Issued	$68,305,000	$66,524,182	$44,677,000	$44,677,000
Tangible Book Value	$45,388,000	$82,949,000	$69,739,000	$106,343,000
Invested Capital	$45,388,000	$82,949,000	$69,739,000	$106,343,000
Working Capital	$43,734,000	$81,626,000	$66,972,000	$103,476,000
Capital Lease Obligations	$832,000	$1,523,000	$2,149,000	$2,715,000
Total Capitalization	$45,388,000	$82,949,000	$69,739,000	$106,343,000
Additional Paid In Capital	$475,361,000	$467,087,000	$409,343,000	$404,834,000
Capital Stock	$7,000	$7,000	$4,000	$4,000
Common Stock	$7,000	$7,000	$4,000	$4,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$102,000	$813,000	$1,458,000	$2,040,000
Current Capital Lease Obligation	$730,000	$710,000	$691,000	$675,000
Pensionand Other Post Retirement Benefit Plans Current	$2,430,000	$2,746,000	$2,737,000	$1,849,000
Current Accrued Expenses	$4,403,000	$5,151,000	$5,046,000	$3,328,000
Net PPE	$1,207,000	$2,067,000	$2,946,000	$3,520,000
Accumulated Depreciation	$-4,467,000	$-4,137,000	$-3,752,000	$-3,413,000
Gross PPE	$5,674,000	$6,204,000	$6,698,000	$6,933,000
Leases	$2,568,000	$2,568,000	$2,568,000	$2,560,000
Other Properties	$2,055,000	$2,583,000	$3,063,000	$3,307,000
Machinery Furniture Equipment	$1,051,000	$1,053,000	$1,067,000	$1,066,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$40,834,000	$40,276,000	$53,168,000	$88,920,000

Fetched: 2026-06-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-37,967,000	$-37,773,000	$-31,469,000	$-34,826,000
Operating Activities
Operating Cash Flow	$-37,923,000	$-37,693,000	$-30,887,000	$-33,820,000
Cash Flow From Continuing Operating Activities	$-37,923,000	$-37,693,000	$-30,887,000	$-33,820,000
Operating Gains Losses	-	-	-	$1,000
Investing Activities
Capital Expenditure	$-44,000	$-80,000	$-582,000	$-1,006,000
Investing Cash Flow	$1,342,000	$13,728,000	$36,195,000	$38,149,000
Cash Flow From Continuing Investing Activities	$1,342,000	$13,728,000	$36,195,000	$38,149,000
Capital Expenditure Reported	$-44,000	$-80,000	$-582,000	$-1,006,000
Net Other Investing Changes	-	-	-	$114,000
Financing Activities
Issuance Of Capital Stock	$0	$53,407,000	$0	$0
Financing Cash Flow	$2,581,000	$53,780,000	$0	$75,000
Cash Flow From Continuing Financing Activities	$2,581,000	$53,780,000	$0	$75,000
Net Common Stock Issuance	$0	$53,407,000	$0	$0
Common Stock Issuance	$0	$53,407,000	$0	$0
Other
Income Tax Paid Supplemental Data	$1,000	$1,000	$1,000	$2,000
End Cash Position	$17,470,000	$51,470,000	$21,655,000	$16,347,000
Beginning Cash Position	$51,470,000	$21,655,000	$16,347,000	$11,943,000
Changes In Cash	$-34,000,000	$29,815,000	$5,308,000	$4,404,000
Proceeds From Stock Option Exercised	$2,581,000	$373,000	$0	$75,000
Net Investment Purchase And Sale	$1,386,000	$13,808,000	$36,777,000	$39,041,000
Sale Of Investment	$73,246,000	$37,371,000	$106,861,000	$130,274,000
Purchase Of Investment	$-71,860,000	$-23,563,000	$-70,084,000	$-91,233,000
Change In Working Capital	$2,179,000	$2,633,000	$6,568,000	$-380,000
Change In Other Current Liabilities	$-691,000	$-626,000	$-566,000	$-446,000
Change In Other Current Assets	$-480,000	$1,210,000	$651,000	$-603,000
Change In Payables And Accrued Expense	$2,202,000	$2,985,000	$2,831,000	$1,348,000
Change In Prepaid Assets	$557,000	$-452,000	$3,169,000	$-443,000
Change In Receivables	$591,000	$-484,000	$483,000	$-236,000
Stock Based Compensation	$5,693,000	$4,760,000	$4,509,000	$4,256,000
Amortization Of Securities	$-848,000	$-598,000	$-921,000	$632,000
Depreciation Amortization Depletion	$904,000	$943,000	$398,000	$236,000
Depreciation And Amortization	$904,000	$943,000	$398,000	$236,000
Depreciation	$904,000	$943,000	$398,000	$236,000
Net Income From Continuing Operations	$-45,851,000	$-45,431,000	$-41,441,000	$-38,704,000
Other Non Cash Items	-	-	-	$139,000
Repayment Of Debt	-	-	-	-
Issuance Of Debt	-	-	-	-
Net Issuance Payments Of Debt	-	-	-	-
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Payments	-	-	-	-
Long Term Debt Issuance	-	-	-	-
Asset Impairment Charge	-	-	-	-
Gain Loss On Investment Securities	-	-	-	-

Fetched: 2026-06-15